J. Jakobsen

发表

Correlation of MET-Receptor Overexpression with MET Gene Amplification and Patient Outcome in Malignant Mesothelioma

E. Santoni-Rugiu, J. Ravn, J. Sørensen, 2021, International journal of molecular sciences.

Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients

E. Santoni-Rugiu, J. Sørensen, J. Jakobsen, 2013, Cancer Chemotherapy and Pharmacology.

Use of TUBB3 for patient stratification and prognosis in lung cancer

E. Santoni-Rugiu, J. Sørensen, J. Jakobsen, 2015 .

Heart rate variation in patients treated with antidepressants. An index of anticholinergic effects?

P. Vestergaard, J. Jakobsen, P. Hauksson, 2004, Psychopharmacology.

Cholinergic dysfunction of heart, pupil, salivary glands, and urinary bladder in healthy volunteers during long-term treatment with clomipramine

P. Vestergaard, U. Bartels, E. Kristensen, 2004, Psychopharmacology.

Review on clinical trials of targeted treatments in malignant mesothelioma

J. Sørensen, J. Jakobsen, 2011, Cancer Chemotherapy and Pharmacology.

Clinical impact of ki-67 labeling index in non-small cell lung cancer.

J. Sørensen, Jan Nyrop Jakobsen, Jens Benn Sørensen, 2013, Lung cancer.

Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance

E. Santoni-Rugiu, J. Sørensen, L. Melchior, 2019, Cancers.

Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment

E. Santoni-Rugiu, J. Sørensen, L. Melchior, 2018, Oncotarget.

1 Intrinsic resistance to EGFR-tyrosine kinase 2 inhibitors in EGFR-mutant non-small cell lung 3 cancer : differences and similarities with acquired 4 resistance 5

E. Santoni-Rugiu, J. Sørensen, L. Melchior, 2019 .

Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer

J. Sørensen, J. Jakobsen, 2012, Cancer Chemotherapy and Pharmacology.

Irinotecan and bevacizumab in recurrent glioblastoma multiforme

H. Poulsen, M. Stockhausen, U. Lassen, 2011, Expert opinion on pharmacotherapy.

Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer

E. Santoni-Rugiu, J. Sørensen, J. Jakobsen, 2014, Journal of Cancer Research and Clinical Oncology.

Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancer

E. Santoni-Rugiu, J. Sørensen, J. Jakobsen, 2013, Cancer Chemotherapy and Pharmacology.

Prevention of chemotherapy-induced nausea and vomiting in elderly cancer patients.

J. Herrstedt, J. Jakobsen, 2009, Critical reviews in oncology/hematology.

Customizing chemotherapy in thoracic malignancies based on ERCC1 expression

J. Sørensen, Z. G. Zimling, J. Jakobsen, 2013 .

Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer.

E. Santoni-Rugiu, J. Ravn, J. Sørensen, 2013, European journal of cancer.

Surgery for NSCLC stages T1-3N2M0 having preoperative pathologically verified N2 involvement: A prospective randomized multinational phase III trial by the Nordic Thoracic Oncology Group.

O. Hansen, T. Palshof, B. Bergman, 2013 .

Differences in RRM1 protein expression between diagnostic biopsies and resection specimens, and changes during carboplatin and paclitaxel treatment, in non‐small‐cell lung cancer

E. Santoni-Rugiu, J. Sørensen, J. Jakobsen, 2014, Histopathology.

Autonomic function in parkinsonian patients relates to duration of disease

N. Christensen, E. Dupont, L. Ørskov, 1987, Neurology.

Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients

I. Christensen, H. Poulsen, T. Urup, 2018, Journal of Neuro-Oncology.